We transform critical care medicine by developing innovative and effective therapies based on alkaline phosphatase (RESCAP®). We are guided by our core values of loyalty towards relationships, accuracy, and high scientific commitment, which underpin everything we do. Our goal is to create a positive impact on the world by bringing new hope to patients and their families through safe, effective, and accessible treatments that improve outcomes and enhance quality of life.
Revolutionize critical care medicine through RESCAP®. We envision a world where RESCAP® improves patient outcomes, reduces mortality, and enhances quality of life. We are committed to scientific excellence, ethical standards, and building lasting relationships with patients, healthcare professionals, regulators, and investors.
Alloksys’ strategy is to develop RESCAP® as a transformative therapy in critical care medicine. We will achieve this by conducting rigorous research and development, building strong relationships with key stakeholders, and maintaining the highest ethical and scientific standards. We will seek regulatory approval for RESCAP® in indications with high unmet medical need and significant market potential, prioritizing those where RESCAP® has demonstrated the most promising results. We will also explore new indications and production methods for RESCAP®, leveraging our scientific expertise and innovation capabilities.
It all began with a strong belief in the potential of RESCAP® to revolutionize healthcare.
Discovery of functionality of AP as an enzyme that detoxifies LPS.
Founding of PharmaAware and its merger with AMPharma to AMPHolding.
Founding of ALLOKSYS Life Sciences BV and start of the APPIRED 1 clinical study with RESCAP® in critical care.
Continuation of APPIRED 1, start and completion of APPIRED1b and APPIRED2 clinical studies with RESCAP® in critical care, and start of the REUMAP pilot study with RESCAP® in rheumatoid arthritis.
Completion of REUMAP pilot study, development of Recombinant human RESCAP, and founding of AMRIF BV.
Phase 1 clinical study / pharmaco kinetics study of hRESCAP, start of APHIRI clinical study with RESCAP® in kidney transplantation, and start of APPIRED 3 clinical study with RESCAP® in critical care.
Continuation of APPIRED 3 and APHIRI clinical studies, start of MAP4B clinical study with RESCAP® in burn wounds, and start and completion of a COVID study.
Interim results of APPIRED 3 study, start of APhIRI 2 study in kidney transplantation, and continuation of MAP4B and APPIRED 3 studies.
The Alloksys team is committed to bringing RESCAP® to market and making it widely available for those who could benefit from it.
President
CFO
CSO
Scientific Director
Scientific Director
MD
QP
1. Scientific Excellence:
We are committed to rigorous scientific research and development to generate strong clinical evidence of the safety and efficacy of our therapies. We strive for scientific excellence in all our activities, from preclinical research to clinical trials and beyond.
2. Patient-Centered:
Patients and their families are at the center of everything we do. We are committed to developing therapies that meet their needs and improve their quality of life. We listen to their voices and engage with them in a meaningful way throughout the drug development process.
3. Collaboration:
We believe that successful drug development requires collaboration across disciplines, organizations, and geographies. We work closely with our partners, stakeholders, and regulators to ensure that our therapies are safe, effective, and accessible.
4. Ethics and Integrity:
We maintain the highest ethical and professional standards in all our activities, from scientific research to business operations. We operate with transparency, honesty, and integrity, putting the interests of patients and stakeholders first.
5. Innovation:
We embrace innovation and creativity in all aspects of our work. We strive to be at the forefront of scientific discovery and to bring novel therapies to patients in need. We continuously challenge ourselves to think outside the box and to find new solutions to unmet medical needs.
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
